Skip to content

Released Mar 10, 2023, before the open

10-K filed Mar 10, 2023, 69 days after period end · 0001493152-23-007178

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derivedno prior Q4 2021 on fileno prior Q3 2022 on file
Net Income-$2.23MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,560,833N/M
Operating Cash Flowderived-$1,838,914N/M
Free Cash Flowderived-$1,935,646—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020Q4 2019derived from reported figures
Revenue$0.00—$0.00$0.00
Net Income-$2.23M$12.62M-$4.51M-$3.29M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR